This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

A Clinical Paradox

Jonathan Abrams, MD

JAMA. 1981;246(14):1557-1558.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

A DILEMMA exists regarding the usefulness of long-acting nitrate preparations in patients with angina pectoris or congestive heart failure and the present Food and Drug Administration approved package inserts (regulatory monographs), outlining nitrate dosage regimens and clinical indications. This group of drugs, whether given orally or topically, has been documented to be bioavailable and clinically effective for four to six hours or longer.¹ Yet the FDA continues to classify all oral long-acting nitrate preparations as being only "possibly effective." In addition, maximal dosages currently recommended by the pharmaceutical manufacturers are considerably smaller than the amounts found to be safe, necessary, and efficacious in a variety of recent investigations.^2,3 Finally, promotional literature, including the package insert, may not recommend nitrates for use in vasodilator therapy of congestive heart failure. No pharmaceutical company has yet submitted a New Drug Application to the FDA for use of any long-acting nitrate in . . . [Full Text PDF of this Article]

Author Affiliations
From the Division of Cardiology, Department of Medicine, the University of New Mexico School of Medicine, Albuquerque.

Footnotes
Reprint requests to Division of Cardiology, University of New Mexico School of Medicine, Albuquerque, NM 87131 (Dr Abrams).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?